Ventripoint Diagnostics Ltd- FDA Approved now

Will certainly be nice to see this Cinderella story unfold

May 25, 2015) - Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE:VPT) is pleased to announce that it has received Marketing Clearance from the U.S. Food & Drug Administration ("FDA") for the expanded Indications for Use of its VMS(TM) product which states; "The VMS system is indicated for use where RV (right ventricle) volumes and ejection fractions are warranted or desired."

"This change in use criteria means physicians in the U.S. can now use the VMS on patients that they believe will benefit from assessment of RV function...

Previously the VMS was limited in use on adults with known pulmonary arterial hypertension (PAH), which is newly diagnosed in approximately 200,000 individuals each year in the U.S. Now the VMS can be used on the more than 20,000,000 people that suffer from heart disease.
....